Study of Atezolizumab Therapy to Identify Biomarkers and Survival Benefits in Adults with Recurrent Glioblastoma

What this Trial Is About

Researchers are studying whether neoadjuvant atezolizumab therapy can benefit adults with recurrent glioblastoma who have a low tumor mutational burden. This phase 2 trial addresses the poor prognosis of recurrent glioblastoma, where current treatments result in less than 20% two-year survival. The study explores the complex interaction between the immune system and glioblastoma, focusing on molecular factors that may influence response to immunotherapy. Participants will receive one dose of atezolizumab before surgical tumor removal. After surgery, tumor tissue will be analyzed to classify patients by low or high tumor mutational burden. All participants continue to receive atezolizumab post-surgery until disease progression, unacceptable side effects, death, or withdrawal from the study. The trial compares survival outcomes between low and high mutational burden groups to evaluate if low burden correlates with better survival. Throughout the study, participants undergo biological specimen collection and molecular testing to understand immune responses. Researchers monitor safety by tracking adverse events related to atezolizumab and assess progression-free survival using specific criteria. Survival is followed for up to 24 months after treatment start. Patients provide informed consent and receive regular evaluations to measure treatment impact and side effects during the study period.

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial